A sporadic Alzheimer's blood-brain barrier model for developing ultrasound-mediated delivery of Aducanumab and anti-Tau antibodies
Year: 2022
Type: article
Abstract: Rationale: The blood-brain barrier (BBB) is a major impediment to therapeutic intracranial drug delivery for the treatment of neurodegenerative diseases, including Alzheimer's disease (AD).Focused ultrasound applied together with microbubbles (FUS +MB ) is a novel technique to transiently open the BBB and increase drug delivery.Evidence suggests that FUS +MB is safe, however, the effects of FUS +MB on human BBB cells, especially in the context of AD, remain sparsely investigated.In addition, there currently are no cell platforms to test for FUS +MB -mediated drug delivery.Methods: Here we generated BBB cells (induced brain endothelial-like cells (iBECs) and astrocytes (iAstrocytes)) from apolipoprotein E gene allele E4 (APOE4, high sporadic AD risk) and allele E3 (APOE3, lower AD risk) carrying patient-derived induced pluripotent stem cells (iPSCs).We established mono-and co-culture models of human sporadic AD and control BBB cells to investigate the effects of FUS +MB on BBB cell phenotype and to screen for the delivery of two potentially therapeutic AD antibodies, an Aducanumab-analogue (Aduhelm TM ; anti-amyloid-β) and a novel anti-Tau antibody, RNF5.We then developed a novel hydrogel-based 2.5D BBB model as a step towards a more physiologically relevant FUS +MB drug delivery platform.Results: When compared to untreated cells, the delivery of Aducanumab-analogue and RNF5 was significantly increased (up to 1.73 fold), across the Transwell-based BBB models following FUS +MB treatment.Our results also demonstrated the safety of FUS +MB indicated by minimal changes in iBEC transcriptome as well as little or no changes in iBEC or iAstrocyte viability and inflammatory responses within the first 24 h post FUS +MB .Furthermore, we demonstrated successful iBEC barrier formation in our novel 2.5D hydrogel-based BBB model with significantly increased delivery (1.4 fold) of Aducanumab-analogue following FUS +MB .Conclusion: Our results demonstrate a robust and reproducible approach to utilize patient cells for FUS +MB -mediated drug delivery screening in vitro.With such a cell platform for FUS +MB research previously not reported, it has the potential to identify novel FUS +MB -deliverable drugs as well as screen for cell-and patient-specific effects of FUS +MB , accelerating the use of FUS +MB as a therapeutic modality in AD.
Source: Theranostics
DOI: 10.7150/thno.72685
Authors: Joanna M. Wasielewska(Conceptualization, Investigation, Methodology, Visualization, Writing – original draft, Writing – review & editing), Juliana C. S. Chaves(Investigation, Methodology), Rebecca L. Johnston(Investigation, Methodology, Visualization, Writing – original draft), Laura A. Milton(Methodology, Writing – review & editing), Damián Hernández(Methodology), Liyu Chen(Methodology), Jae Song(Methodology), Wendy Lee(Methodology), Gerhard Leinenga(Methodology), Rebecca M. Nisbet(Methodology, Supervision), Alice Pébay(Funding acquisition, Supervision), Jürgen Götz(Funding acquisition, Project administration, Supervision, Writing – review & editing), Anthony R. White(Conceptualization, Funding acquisition, Project administration, Supervision, Writing – original draft, Writing – review & editing), Lotta E. Oikari(Conceptualization, Investigation, Methodology, Supervision, Visualization, Writing – original draft, Writing – review & editing)
Language: English
Subfield: Neurology
Field: Neuroscience
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $1,671
OpenAlex ID: W4307429836
